I really like what I am reading. I guess a few of us...

I really like what I am reading. I guess a few of us actually guessed it half right being Pharmocann products for global sales & hemp/MM products into Asia. I'm guessing through these partnerships other deals will materialise like perhaps  the Pharmocann products to be sold into Canada or Canntab into Israel (IMO). I'm also wondering if this faster track to revenue will potentially lead to the purchase of Medcan with cash rather than dilution. I guess it opens the doors to many possibilities. Funny how the usual suspects find this deal as another "crazy" announcement, trashing management & trying to scaremonger around listing etc. I guess we should expect no less but would be great to get some more facts around this in the next few weeks. Hopefully the 11th will be the final prospectus or here's hoping!

BioHealth Pharmaceuticals is one of a few in an elite group of TGA GMP approved Australian Pharmaceutical companies registered to produce and manufacture pharmaceuticals and complementary medicines in Australia.

Establishing a partnership with Bio Health

The MOU between Bio Health and Cann Global is entered into to assist Cann Global to produce in the short-term high volumes of product to distribute into the Australian and Asian marketplaces, initially targeting the established markets of Hong Kong, Japan and Korea. Further opportunities exist to leverage relationships with chemists, health food conglomerates and supermarket chains in the region.

Peter Edwards, the Production and Development Manager of Cann Global’s Food Division said, “Bio Health Pharmaceuticals are clearly a perfect fit with Cann Global. BioHealth pharmaceuticals is a genuinely dynamic company, innovative, Asian focused, well respected and have impeccable regulatory credentials. High quality Pharmaceutical and Nutraceutical manufacturing practices are available to Cann Global right now, rather than later.”

“In addition to now having the ability to immediately mass produce the Canntab and Pharmocann medical Cannabis products, together, we are about to produce high volume co-branded nutraceutical products under the Bio Health Pharmaceuticals and VitaHemp banners, initially targeting mature Hemp markets in Hong Kong, Japan & Korea. There are positive opportunities for both companies in existing markets, whilst exploring new, particularly large Asian chemist and health food conglomerates, including in the massive Chinese markets.”

Highlights:

• BioHealth will manufacture from its facilities in Sydney our CannTab Medical Cannabis formulations and proprietary medical products, the Pharmocann range of medical products, and the full range of Hemp Seed oil capsules and nutraceuticals, on commercial terms as a contract manufacturer of these products

• CannTab and Pharmocann Executives to visit the Manufacturing facilities to oversee the production of their respective proprietary range of tablets and products

• Cann Global will manage the business plan to manufacture and distribute the Canntab and Pharmocann products in Australia and Asia

• Further consideration of possible co-branding Hemp oil nutraceuticals with Gel and Vegecap Hemp Seed and CBD oil tablets for the Australian and International export marketBio Health specialises in complementary medicines, health and skincare products. Our fully-equipped facility is able to research, develop, and manufacture safe, reliable and affordable products for existing markets, as well as OEM customers, throughout Australia and overseas.
  Pharmocann:
  Our latest developments are breakthrough treatments of Hydro-Gel products to some of the most painful diseases. We are currently developing a line of Hydro-Gel products for acute dermatological diseases, and a Hydro-Gel food additive for relieving the suffering of inflammatory bowl diseases. The line is fully natural, shows no side effects and is reported by the patients to have reduced their suffering substantially.